The estimated Net Worth of Robert Coffman is at least 1.81 百万$ dollars as of 28 February 2019. Robert Coffman owns over 63,202 units of Dynavax Technologies stock worth over 848,449$ and over the last 20 years Robert sold DVAX stock worth over 961,124$.
Sign up
Robert Coffman DVAX stock SEC Form 4 insiders trading
Robert has made over 15 trades of the Dynavax Technologies stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert sold 63,202 units of DVAX stock worth 570,714$ on 28 February 2019.
The largest trade Robert's ever made was selling 63,202 units of Dynavax Technologies stock on 28 February 2019 worth over 570,714$. On average, Robert trades about 6,162 units every 127 days since 2004. As of 28 February 2019 Robert still owns at least 77,768 units of Dynavax Technologies stock.
You can see the complete history of Robert Coffman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Coffman's mailing address?
Robert's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGY CORPORATION, 2929 SEVENTH STREET, SUITE 130, BERKELEY, CA, 94710.
Insiders trading at Dynavax Technologies
Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. Hack、Partners L P/Ilbiotechnolog...、James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.
What does Dynavax Technologies do?
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
What does Dynavax Technologies's logo look like?
Complete history of Robert Coffman stock trades at Dynavax Technologies
Dynavax Technologies executives and stock owners
Dynavax Technologies executives and other stock owners filed with the SEC include:
-
Ryan Spencer,
CEO & Director -
David F. Novack,
Pres & COO -
Dr. Robert Janssen,
Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs -
Michael S. Ostrach,
Advisor -
John Slebir,
Sr. VP & Gen. Counsel -
Nicole Arndt,
Sr. Mang. of Investor Relations -
Meg Smith,
VP Sales & Operations -
Steven N. Gersten,
Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec. -
Heather Rowe,
VP of Investor Relations & Corp. Communications -
Jeff P. Coon,
Sr. VP of HR & Admin. -
Justin Burgess,
Principal Accounting Officer & Controller -
Kelly MacDonald,
Sr. VP & CFO -
Laura Brege,
Director -
Eddie Gray,
CEO and Director -
Arnold L Oronsky,
Director -
Stanley A Plotkin,
Director -
Daniel L Kisner,
-
Dennis Carson,
Director -
Natale S Ricciardi,
Director -
David Louis Johnson,
Vice President -
Michael S Ostrach,
Senior Vice President -
Elaine D Sun,
-
Francis Cano,
-
Peter R. Paradiso,
-
Peggy V Phillips,
-
Brent Mac Gregor,
-
Julia Marie Eastland,
-
Scott Dunseth Myers,
-
Partners L P/Ilbiotechnolog...,
-
Nest Gary A Van,
Vice President -
Dino Dina,
President and CEO -
Denise Gilbert,
Director -
Martin E Sanders,
EVP, Chief Development Officer -
James Edeerfield Capital Lp...,
-
Partners L P/Ilbiotechnolog...,
-
James Edeerfield Capital Lp...,
-
James Edeerfield Capital Lp...,
-
Deborah A Smeltzer,
VP Operations & CFO -
Timothy G Henn,
Vice President -
Zbigniew Janowicz,
Director -
Daniel Janney,
Director -
Stephen F Tuck,
Vice President -
Nancy L Buc,
Director -
J Tyler Martin,
VP Clinical Development & CMO -
Christine R Larson,
VP and Chief Financial Officer -
Capital Partners Lpsymphony...,
-
Jennifer Lew,
VP, Finance & PAO -
Mark Kessel,
Director -
David M Lawrence,
Director -
Daniel J Levitt,
VP and Chief Medical Officer -
James Edeerfield Capital Lp...,
-
Louis C Bock,
Director -
Jan Leschly,
Director -
James E Flynn,
10% owner -
Danielalta California Partn...,
-
Robert Coffman,
VP & Chief Scientific Officer -
David F Novack,
President & COO -
Ryan Spencer,
CEO and Director -
Robert Janssen,
SVP and CMO -
Kelly Mac Donald,
SVP and CFO -
Justin Burgess,
VP Finance & CAO -
Andrew A. F. Hack,